Successful treatment of Cronkhite–Canada syndrome using anti-tumor necrosis factor antibody therapy
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Successful treatment of Cronkhite–Canada syndrome using anti-tumor necrosis factor antibody therapy ; volume:46 ; number:S 01 ; year:2014 ; pages:E476-E477 ; 01
Endoscopy ; 46, Heft S 01 (2014), E476-E477, 01
- Contributor
-
Watanabe, Daisuke
Ooi, Makoto
Hoshi, Namiko
Kohashi, Michitaka
Yoshie, Tomoo
Ikehara, Nobunao
Yoshida, Masaru
Yanagita, Emmy
Yamasaki, Takashi
Itoh, Tomoo
Azuma, Takeshi
- DOI
-
10.1055/s-0034-1377539
- URN
-
urn:nbn:de:101:1-2019050612215146736074
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:55 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Watanabe, Daisuke
- Ooi, Makoto
- Hoshi, Namiko
- Kohashi, Michitaka
- Yoshie, Tomoo
- Ikehara, Nobunao
- Yoshida, Masaru
- Yanagita, Emmy
- Yamasaki, Takashi
- Itoh, Tomoo
- Azuma, Takeshi
Other Objects (12)
Successful treatment with anti-tumor necrosis factor alpha for reactive small-bowel amyloidosis
Remission of Behcet's disease with anti-tumor necrosis factor monoclonal antibody therapy: a case report
Golimumab: A Novel Anti-Tumor Necrosis Factor
T cell lymphoproliferative disorders associated with anti-tumor necrosis factor alpha antibody therapy for ulcerative colitis: literature summary
Anti-tumor necrosis factor therapy in inflammatory bowel disease : 15 tables
Successful conservative treatment for massive tracheal necrosis after lung segmentectomy
Update on intravitreal anti-tumor necrosis factor alpha therapies for ocular disorders
Ipilimumab augments antitumor activity of bispecific antibody-armed T cells
Anti-tumor action of tumor necrosis factor against Bomirski Ab melanoma in hamsters
Anti-tumor necrosis factor patent expiration and the risks of biocopies in clinical practice
Factors that influence rheumatologists’ anti-tumor necrosis factor alpha prescribing decisions: a qualitative study
Evolution of the antagonistic tumor necrosis factor receptor one-specific antibody ATROSAB
Successful treatment with anti-tumor necrosis factor alpha for reactive small-bowel amyloidosis
Remission of Behcet's disease with anti-tumor necrosis factor monoclonal antibody therapy: a case report
Golimumab: A Novel Anti-Tumor Necrosis Factor
T cell lymphoproliferative disorders associated with anti-tumor necrosis factor alpha antibody therapy for ulcerative colitis: literature summary
Anti-tumor necrosis factor therapy in inflammatory bowel disease : 15 tables
Successful conservative treatment for massive tracheal necrosis after lung segmentectomy
Update on intravitreal anti-tumor necrosis factor alpha therapies for ocular disorders
Ipilimumab augments antitumor activity of bispecific antibody-armed T cells
Anti-tumor action of tumor necrosis factor against Bomirski Ab melanoma in hamsters
Anti-tumor necrosis factor patent expiration and the risks of biocopies in clinical practice
Factors that influence rheumatologists’ anti-tumor necrosis factor alpha prescribing decisions: a qualitative study
Evolution of the antagonistic tumor necrosis factor receptor one-specific antibody ATROSAB
Successful treatment with anti-tumor necrosis factor alpha for reactive small-bowel amyloidosis
Remission of Behcet's disease with anti-tumor necrosis factor monoclonal antibody therapy: a case report
Golimumab: A Novel Anti-Tumor Necrosis Factor
T cell lymphoproliferative disorders associated with anti-tumor necrosis factor alpha antibody therapy for ulcerative colitis: literature summary
Anti-tumor necrosis factor therapy in inflammatory bowel disease : 15 tables
Successful conservative treatment for massive tracheal necrosis after lung segmentectomy
Update on intravitreal anti-tumor necrosis factor alpha therapies for ocular disorders
Ipilimumab augments antitumor activity of bispecific antibody-armed T cells
Anti-tumor action of tumor necrosis factor against Bomirski Ab melanoma in hamsters
Anti-tumor necrosis factor patent expiration and the risks of biocopies in clinical practice
Factors that influence rheumatologists’ anti-tumor necrosis factor alpha prescribing decisions: a qualitative study